What Are Primary Sclerosing Cholangitis (PSC) and Primary Biliary Cirrhosis (PBC)?

P

rimary sclerosing cholangitis is a chronic disorder. It affects the liver with inflammation that leads to permanent scarring (cirrhosis) and inhibits liver function. How the disorder develops is unclear, but it may arise after unrelated infections. Scarring is its principal feature.

Primary biliary cirrhosis is a chronic autoimmune disease. It produces progressive destruction of the liver’s bile ducts by the immune system. This begins with inflammation, which can progress and reduce liver function. Medication delays the disorder’s advance.

Both diseases have similar symptoms and prognosis. However, they develop for different reasons, produce damage in different ways, and are prevalent in distinct patient populations.

Match to PBC/PSC Clinical Trials

  • Access to cutting-edge treatments
  • Latest clinical trials
  • Find trials in your area

What Conditions Are Primary Sclerosing Cholangitis and Primary Biliary Cirrhosis Associated With?

Primary sclerosing cholangitis produces fever, chills, and abdominal pain. Inability of the body to properly manage bile may turn the skin yellow temporarily. The majority of people with the disorder also have inflammatory bowel disease. Experts believe there is a strong genetic aspect to who develops the condition, but this disposition does not guarantee someone will get it.

Primary biliary cirrhosis has symptoms similar to primary sclerosing cholangitis. Symptoms may develop slowly over five to 20 years. In the most severe cases, a liver transplant is required. Diagnosis is most likely after age 40. Approximately 90% of all patients with the disorder are women, and prevalence is higher in those of European descent.

Many cases of both primary biliary cirrhosis and primary sclerosing cholangitis are diagnosed before symptoms are severe. This is because about 70% of primary biliary cirrhosis patients experience serious fatigue that leads them to see a doctor. Fatigue is also the most common symptom in its sister disease and tends to be noticed first.

Neither condition should be confused with acute cholangitis. Acute cholangitis is characterized by bile duct damage caused by temporary blockage of the ducts. The blockage inhibits bile flow, which leads to infection. Acute cholangitis requires emergency hospitalization.

Primary Sclerosing Cholangitis and Primary Biliary Cirrhosis Lifestyle Changes and Recovery

Primary sclerosing cholangitis and primary biliary cirrhosis are forms of liver disease. Lifestyle changes may be necessary based on the liver damage. Patients with either disease often benefit from discontinuing alcohol use, removing a possible source of liver damage.

No cure exists for these diseases. Care focuses on monitoring and managing complications over time. With appropriate medical intervention, liver function can be preserved for many years. The appropriate treatments differ based on the patient’s age and comorbid conditions.

What Research Currently Exists Around Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis?

Ongoing medical research about primary biliary cirrhosis focuses on understanding the genetic underpinnings of the disorder: Its incidence, prevalence, and changes in blood test results that can predict its presence during the asymptomatic stages.

Research about primary sclerosing cholangitis is launched regularly. In 2016, the disease saw its largest-ever genetic study. That work produced new findings pertaining to four parts of the genome associated with the disease, potentially pointing the way to treatment.

Current Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis Clinical Trials

The following primary biliary cirrhosis clinical studies and primary sclerosing cholangitis clinical trials come from ClinicalTrials.gov. If you have a clinical study you would like featured, please contact our team.

  • Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Patients With PBC
    on October 20, 2020 at 4:00 pm

    Condition:   Liver Cirrhosis, BiliaryInterventions:   Drug: Obeticholic acid;   Drug: Bezafibrate 200 MG;   Drug: OCA Placebo;   Drug: Bezafibrate 200 mg Placebo;   Drug: Bezafibrate 400 MG;   Drug: Bezafibrate 400 mg PlaceboSponsor:   Intercept PharmaceuticalsRecruiting

  • Umbilical Cord Derived Mesenchymal Stem Cell (UC -MSC) Transplantation for Children Suffering From Biliary Atresia
    on August 21, 2020 at 4:00 pm

    Condition:   Primary Biliary CirrhosisIntervention:   Biological: Umbilical Cord Derived Mesenchymal Stem Cell (UC -MSC) TransplantationSponsors:   Vinmec Research Institute of Stem Cell and Gene Technology;   Children's Hospital Number 2, Ho Chi Minh City, VietnamRecruiting

  • Linerixibat Long-term Safety and Tolerability Study
    on November 18, 2019 at 5:00 pm

    Condition:   CholestasisIntervention:   Drug: LinerixibatSponsor:   GlaxoSmithKlineRecruiting

  • Study to Evaluate the Safety and Efficacy of Oral CR845 (Difelikefalin) in Patients With Primary Biliary Cholangitis (PBC) and Moderate-to-Severe Pruritus
    on June 21, 2019 at 4:00 pm

    Condition:   Cholestatic PruritusInterventions:   Drug: CR845 1.0 mg;   Drug: PlaceboSponsor:   Cara Therapeutics, Inc.Recruiting

  • Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity
    on May 7, 2019 at 4:00 pm

    Conditions:   SCAD;   Addison Disease;   Ankylosing Spondylitis;   Antiphospholipid Antibody Syndrome;   Celiac Disease;   Crohn Disease;   Dermatomyositis;   Polymyositis;   Guillain-Barre Syndrome;   Hepatitis, Autoimmune;   Graves Disease;   Hashimoto Thyroiditis;   Multiple Sclerosis;   Myasthenia Gravis;   Pernicious Anemia;   Polymyalgia Rheumatica;   Primary Biliary Cirrhosis;   Psoriasis;   Rheumatoid Arthritis;   Systemic Sclerosis;   Sjögren Syndrome;   Systemic Lupus Erythematosus;   Takayasu Arteritis;   Type 1 Diabetes Mellitus;   Ulcerative Colitis;   Uveitis;   Vasculitis;   Vitiligo;   RaynaudIntervention:   Sponsor:   Mayo ClinicRecruiting

  • Repeatability and Reproducibility of Multiparametric MRI
    on November 16, 2018 at 5:00 pm

    Conditions:   Liver Diseases;   Primary Biliary Cirrhosis;   Non-Alcoholic Fatty Liver Disease;   Non-Alcoholic Steatohepatitis;   Cirrhosis;   Hemochromatosis;   Viral Hepatitis;   Autoimmune Hepatitis;   Primary Sclerosing CholangitisIntervention:   Device: LiverMultiScanSponsor:   PerspectumRecruiting

  • Performance of Scoring Systems in Chinese Patients With Primary Biliary Cholangitis (PBC) on Ursodeoxycholic Acid
    on June 15, 2017 at 4:00 pm

    Condition:   Primary Biliary Cholangitis (PBC)Intervention:   Drug: Ursodeoxycholic AcidSponsors:   Humanity and Health Research Centre;   Beijing 302 HospitalRecruiting

  • Remission Induction of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome
    on October 18, 2016 at 4:00 pm

    Conditions:   Hepatitis, Autoimmune;   Cholangitis;   Liver Cirrhosis, Biliary;   CholestasisInterventions:   Drug: Ursodeoxycholic acid combination of immunosuppressive agents;   Drug: Ursodeoxycholic AcidSponsor:   Xiaoli FanRecruiting

  • sCD163 in PBC Patients - Assessment of Treatment Response
    on October 13, 2016 at 4:00 pm

    Conditions:   Primary Biliary Cirrhosis;   Liver Inflammation;   Ursodeoxycholic AcidInterventions:   Other: Blood samples;   Device: Fibroscan;   Other: Questionnaires;   Biological: Liver biopsySponsor:   University of AarhusRecruiting

  • sCD163 in PBC Patients - Assessment of Disease Severity and Prognosis
    on October 5, 2016 at 4:00 pm

    Conditions:   Primary Biliary Cirrhosis;   Liver InflammationIntervention:   Other: Blood samples, fibroscan and questionairesSponsor:   University of AarhusRecruiting

  • Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis
    on December 4, 2014 at 5:00 pm

    Condition:   Liver Cirrhosis, BiliaryInterventions:   Drug: Obeticholic Acid (OCA);   Drug: PlaceboSponsor:   Intercept PharmaceuticalsRecruiting

  • Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
    on February 15, 2013 at 5:00 pm

    Conditions:   Rare Disorders;   Undiagnosed Disorders;   Disorders of Unknown Prevalence;   Cornelia De Lange Syndrome;   Prenatal Benign Hypophosphatasia;   Perinatal Lethal Hypophosphatasia;   Odontohypophosphatasia;   Adult Hypophosphatasia;   Childhood-onset Hypophosphatasia;   Infantile Hypophosphatasia;   Hypophosphatasia;   Kabuki Syndrome;   Bohring-Opitz Syndrome;   Narcolepsy Without Cataplexy;   Narcolepsy-cataplexy;   Hypersomnolence Disorder;   Idiopathic Hypersomnia Without Long Sleep Time;   Idiopathic Hypersomnia With Long Sleep Time;   Idiopathic Hypersomnia;   Kleine-Levin Syndrome;   Kawasaki Disease;   Leiomyosarcoma;   Leiomyosarcoma of the Corpus Uteri;   Leiomyosarcoma of the Cervix Uteri;   Leiomyosarcoma of Small Intestine;   Acquired Myasthenia Gravis;   Addison Disease;   Hyperacusis (Hyperacousis);   Juvenile Myasthenia Gravis;   Transient Neonatal Myasthenia Gravis;   Williams Syndrome;   Lyme Disease;   Myasthenia Gravis;   Marinesco Sjogren Syndrome(Marinesco-Sjogren Syndrome);   Isolated Klippel-Feil Syndrome;   Frasier Syndrome;   Denys-Drash Syndrome;   Beckwith-Wiedemann Syndrome;   Emanuel Syndrome;   Isolated Aniridia;   Axenfeld-Rieger Syndrome;   Aniridia-intellectual Disability Syndrome;   Aniridia - Renal Agenesis - Psychomotor Retardation;   Aniridia - Ptosis - Intellectual Disability - Familial Obesity;   Aniridia - Cerebellar Ataxia - Intellectual Disability;   Aniridia - Absent Patella;   Aniridia;   Peters Anomaly - Cataract;   Peters Anomaly;   Potocki-Shaffer Syndrome;   Silver-Russell Syndrome Due to Maternal Uniparental Disomy of Chromosome 11;   Silver-Russell Syndrome Due to Imprinting Defect of 11p15;   Silver-Russell Syndrome Due to 11p15 Microduplication;   Syndromic Aniridia;   WAGR Syndrome;   Wolf-Hirschhorn Syndrome;   4p16.3 Microduplication Syndrome;   4p Deletion Syndrome, Non-Wolf-Hirschhorn Syndrome;   Autosomal Recessive Stickler Syndrome;   Stickler Syndrome Type 2;   Stickler Syndrome Type 1;   Stickler Syndrome;   Mucolipidosis Type 4;   X-linked Spinocerebellar Ataxia Type 4;   X-linked Spinocerebellar Ataxia Type 3;   X-linked Intellectual Disability - Ataxia - Apraxia;   X-linked Progressive Cerebellar Ataxia;   X-linked Non Progressive Cerebellar Ataxia;   X-linked Cerebellar Ataxia;   Vitamin B12 Deficiency Ataxia;   Toxic Exposure Ataxia;   Unclassified Autosomal Dominant Spinocerebellar Ataxia;   Thyroid Antibody Ataxia;   Sporadic Adult-onset Ataxia of Unknown Etiology;   Spinocerebellar Ataxia With Oculomotor Anomaly;   Spinocerebellar Ataxia With Epilepsy;   Spinocerebellar Ataxia With Axonal Neuropathy Type 2;   Spinocerebellar Ataxia Type 8;   Spinocerebellar Ataxia Type 7;   Spinocerebellar Ataxia Type 6;   Spinocerebellar Ataxia Type 5;   Spinocerebellar Ataxia Type 4;   Spinocerebellar Ataxia Type 37;   Spinocerebellar Ataxia Type 36;   Spinocerebellar Ataxia Type 35;   Spinocerebellar Ataxia Type 34;   Spinocerebellar Ataxia Type 32;   Spinocerebellar Ataxia Type 31;   Spinocerebellar Ataxia Type 30;   Spinocerebellar Ataxia Type 3;   Spinocerebellar Ataxia Type 29;   Spinocerebellar Ataxia Type 28;   Spinocerebellar Ataxia Type 27;   Spinocerebellar Ataxia Type 26;   Spinocerebellar Ataxia Type 25;   Spinocerebellar Ataxia Type 23;   Spinocerebellar Ataxia Type 22;   Spinocerebellar Ataxia Type 21;   Spinocerebellar Ataxia Type 20;   Spinocerebellar Ataxia Type 2;   Spinocerebellar Ataxia Type 19/22;   Spinocerebellar Ataxia Type 18;   Spinocerebellar Ataxia Type 17;   Spinocerebellar Ataxia Type 16;   Spinocerebellar Ataxia Type 15/16;   Spinocerebellar Ataxia Type 14;   Spinocerebellar Ataxia Type 13;   Spinocerebellar Ataxia Type 12;   Spinocerebellar Ataxia Type 11;   Spinocerebellar Ataxia Type 10;   Spinocerebellar Ataxia Type 1 With Axonal Neuropathy;   Spinocerebellar Ataxia Type 1;   Spinocerebellar Ataxia - Unknown;   Spinocerebellar Ataxia - Dysmorphism;   Non Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature;   Spasticity-ataxia-gait Anomalies Syndrome;   Spastic Ataxia With Congenital Miosis;   Spastic Ataxia - Corneal Dystrophy;   Spastic Ataxia;   Rare Hereditary Ataxia;   Rare Ataxia;   Recessive Mitochondrial Ataxia Syndrome;   Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature;   Posterior Column Ataxia - Retinitis Pigmentosa;   Post-Stroke Ataxia;   Post-Head Injury Ataxia;   Post Vaccination Ataxia;   Polyneuropathy - Hearing Loss - Ataxia - Retinitis Pigmentosa - Cataract;   Muscular Atrophy - Ataxia - Retinitis Pigmentosa - Diabetes Mellitus;   Non-hereditary Degenerative Ataxia;   Paroxysmal Dystonic Choreathetosis With Episodic Ataxia and Spasticity;   Olivopontocerebellar Atrophy - Deafness;   NARP Syndrome;   Myoclonus - Cerebellar Ataxia - Deafness;   Multiple System Atrophy, Parkinsonian Type;   Multiple System Atrophy, Cerebellar Type;   Multiple System Atrophy;   Maternally-inherited Leigh Syndrome;   Machado-Joseph Disease Type 3;   Machado-Joseph Disease Type 2;   Machado-Joseph Disease Type 1;   Leigh Syndrome;   Late-onset Ataxia With Dementia;   Infection or Post Infection Ataxia;   GAD Ataxia;   Hereditary Episodic Ataxia;   Gliadin/Gluten Ataxia;   Friedreich Ataxia;   Fragile X-associated Tremor/Ataxia Syndrome;   Familial Paroxysmal Ataxia;   Exposure to Medications Ataxia;   Episodic Ataxia With Slurred Speech;   Episodic Ataxia Unknown Type;   Episodic Ataxia Type 7;   Episodic Ataxia Type 6;   Episodic Ataxia Type 5;   Episodic Ataxia Type 4;   Episodic Ataxia Type 3;   Episodic Ataxia Type 1;   Epilepsy and/or Ataxia With Myoclonus as Major Feature;   Early-onset Spastic Ataxia-neuropathy Syndrome;   Early-onset Progressive Neurodegeneration - Blindness - Ataxia - Spasticity;   Early-onset Cerebellar Ataxia With Retained Tendon Reflexes;   Early-onset Ataxia With Dementia;   Childhood-onset Autosomal Recessive Slowly Progressive Spinocerebellar Ataxia;   Dilated Cardiomyopathy With Ataxia;   Cataract - Ataxia - Deafness;   Cerebellar Ataxia, Cayman Type;   Cerebellar Ataxia With Peripheral Neuropathy;   Cerebellar Ataxia - Hypogonadism;   Cerebellar Ataxia - Ectodermal Dysplasia;   Cerebellar Ataxia - Areflexia - Pes Cavus - Optic Atrophy - Sensorineural Hearing Loss;   Brain Tumor Ataxia;   Brachydactyly - Nystagmus - Cerebellar Ataxia;   Benign Paroxysmal Tonic Upgaze of Childhood With Ataxia;   Autosomal Recessive Syndromic Cerebellar Ataxia;   Autosomal Recessive Spastic Ataxia With Leukoencephalopathy;   Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay;   Autosomal Recessive Spastic Ataxia - Optic Atrophy - Dysarthria;   Autosomal Recessive Spastic Ataxia;   Autosomal Recessive Metabolic Cerebellar Ataxia;   Autosomal Dominant Spinocerebellar Ataxia Due to Repeat Expansions That do Not Encode Polyglutamine;   Autosomal Recessive Ataxia, Beauce Type;   Autosomal Recessive Ataxia Due to Ubiquinone Deficiency;   Autosomal Recessive Ataxia Due to PEX10 Deficiency;   Autosomal Recessive Degenerative and Progressive Cerebellar Ataxia;   Autosomal Recessive Congenital Cerebellar Ataxia Due to MGLUR1 Deficiency;   Autosomal Recessive Congenital Cerebellar Ataxia Due to GRID2 Deficiency;   Autosomal Recessive Congenital Cerebellar Ataxia;   Autosomal Recessive Cerebellar Ataxia-pyramidal Signs-nystagmus-oculomotor Apraxia Syndrome;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to WWOX Deficiency;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to TUD Deficiency;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to KIAA0226 Deficiency;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome;   Autosomal Recessive Cerebellar Ataxia With Late-onset Spasticity;   Autosomal Recessive Cerebellar Ataxia Due to STUB1 Deficiency;   Autosomal Recessive Cerebellar Ataxia Due to a DNA Repair Defect;   Autosomal Recessive Cerebellar Ataxia - Saccadic Intrusion;   Autosomal Recessive Cerebellar Ataxia - Psychomotor Retardation;   Autosomal Recessive Cerebellar Ataxia - Blindness - Deafness;   Autosomal Recessive Cerebellar Ataxia;   Autosomal Dominant Spinocerebellar Ataxia Due to a Polyglutamine Anomaly;   Autosomal Dominant Spinocerebellar Ataxia Due to a Point Mutation;   Autosomal Dominant Spinocerebellar Ataxia Due to a Channelopathy;   Autosomal Dominant Spastic Ataxia Type 1;   Autosomal Dominant Spastic Ataxia;   Autosomal Dominant Optic Atrophy;   Ataxia-telangiectasia Variant;   Ataxia-telangiectasia;   Autosomal Dominant Cerebellar Ataxia, Deafness and Narcolepsy;   Autosomal Dominant Cerebellar Ataxia Type 4;   Autosomal Dominant Cerebellar Ataxia Type 3;   Autosomal Dominant Cerebellar Ataxia Type 2;   Autosomal Dominant Cerebellar Ataxia Type 1;   Autosomal Dominant Cerebellar Ataxia;   Ataxia-telangiectasia-like Disorder;   Ataxia With Vitamin E Deficiency;   Ataxia With Dementia;   Ataxia - Oculomotor Apraxia Type 1;   Ataxia - Other;   Ataxia - Genetic Diagnosis - Unknown;   Acquired Ataxia;   Adult-onset Autosomal Recessive Cerebellar Ataxia;   Alcohol Related Ataxia;   Multiple Endocrine Neoplasia;   Multiple Endocrine Neoplasia Type II;   Multiple Endocrine Neoplasia Type 1;   Multiple Endocrine Neoplasia Type 2;   Multiple Endocrine Neoplasia, Type IV;   Multiple Endocrine Neoplasia, Type 3;   Multiple Endocrine Neoplasia (MEN) Syndrome;   Multiple Endocrine Neoplasia Type 2B;   Multiple Endocrine Neoplasia Type 2A;   Atypical Hemolytic Uremic Syndrome;   Atypical HUS;   Wiedemann-Steiner Syndrome;   Breast Implant-Associated Anaplastic Large Cell Lymphoma;   Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA);   Hemophagocytic Lymphohistiocytosis;   Behcet's Disease;   Alagille Syndrome;   Inclusion Body Myopathy With Early-onset Paget Disease and Frontotemporal Dementia (IBMPFD);   Lowe Syndrome;   Pitt Hopkins Syndrome;   1p36 Deletion Syndrome;   Jansen Type Metaphyseal Chondrodysplasia;   Cockayne Syndrome;   Chronic Recurrent Multifocal Osteomyelitis;   CRMO;   Malan Syndrome;   Hereditary Sensory and Autonomic Neuropathy Type Ie;   VCP Disease;   Hypnic Jerking;   Sleep Myoclonus;   Mollaret Meningitis;   Recurrent Viral Meningitis;   CRB1;   Leber Congenital Amaurosis;   Retinitis Pigmentosa;   Rare Retinal Disorder;   KCNMA1-Channelopathy;   Primary Biliary Cirrhosis;   ZMYND11;   Transient Global Amnesia;   Glycogen Storage Disease;   Alstrom Syndrome;   White Sutton Syndrome;   DNM1;   EIEE31;   Myhre Syndrome;   Recurrent Respiratory Papillomatosis;   Laryngeal Papillomatosis;   Tracheal Papillomatosis;   Refsum Disease;   Nicolaides Baraitser Syndrome;   LeukodystrophyIntervention:   Sponsors:   Sanford Health;   National Ataxia Foundation;   International WAGR Syndrome Association;   4p- Support Group;   ML4 Foundation;   Cornelia de Lange Syndrome Foundation;   Stickler Involved People;   Kawasaki Disease Foundation;   Klippel-Feil Syndrome Alliance;   Klippel-Feil Syndrome Freedom;   Hyperacusis Research Limited;   Hypersomnia Foundation;   Kabuki Syndrome Network;   Kleine-Levin Syndrome Foundation;   Leiomyosarcoma Direct Research Foundation;   Marinesco-Sjogren Syndrome Support Group - NORD;   Mucolipidosis Type IV (ML4) Foundation;   People with Narcolepsy 4 People with Narcolepsy (PWN4PWN);   Soft Bones Incorporated;   American Multiple Endocrine Neoplasia Support;   Atypical Hemolytic Uremic Syndrome Foundation;   All Things Kabuki;   Wiedemann-Steiner Syndrome Foundation;   Breast Implant Victim Advocates;   PROS Foundation;   American Behcet's Disease Association;   Alstrom United Kingdom;   Athymia;   Curing Retinal Blindness Foundation;   HSAN1E Society;   1p36 Deletion Support and Awareness;   The Alagille Syndrome Alliance;   Autoinflammatory Alliance;   Beyond Batten;   Bohring-Opitz Syndrome Foundation, INC;   Cockayne Syndrome Network (Share and Care);   CRMO Foundation;   Cure VCP Disease,INC;   FOD Support;   Cystinosis Research Foundation;   Global DARE Foundation;   Hypnic Jerk-Sleep Myoclonus Support Group;   Jansen's Foundation;   KCNMA1 Channelopathy International Advocacy Foundation;   Kawasaki Disease Foundation Australia;   Life with LEMS Foundation;   Lowe Syndrome Association;   The Malan Syndrome Foundation;   Maple Syrup Urine Disease Family Support Group;   International Association for Muscle Glycogen Storage Disease (IamGSD);   Myhre Syndrome Foundation;   DNM1 Families;   Nicolaides Baraitser Syndrome (NCBRS) Worldwide Foundation;   The PBCers Organization;   Pitt Hopkins Research Foundation;   Progressive Familial Intrahepatic Cholestasis Advocacy and Resource Network, Inc;   Recurrent Meningitis Association;   Recurrent Respiratory Papillomatosis Foundation;   Remember the Girls;   Smith-Kingsmore Syndrome Foundation;   SPG Research Foundation;   Team Telomere;   Transient Global Amnesia Project;   The Charlotte & Gwenyth Gray Foundation;   The Cute Syndrome Foundation;   The Maddi Foundation;   White Sutton Syndrome Foundation;   Zmynd11 Gene Disorder;   Cauda Equina Foundation, Inc;   Tango2 Research Foundation;   Noah's Hope - Hope4Bridget Foundation;   Project Sebastian;   SMC1A Epilepsy Foundation;   International Foundation for Gastrointestinal Disorders;   Endosalpingiosis Foundation, IncRecruiting

Conclusion

PBC and PSC are rare and relatively mysterious. Clinical trials are essential for developing primary biliary cirrhosis clinical resources that could arrest progress of the disease. Likewise, new medical research is the clearest path to a cure for primary sclerosing cholangitis.

Match to PBC/PSC Clinical Trials

  • Access to cutting-edge treatments
  • Latest clinical trials
  • Find trials in your area